Complete remission of philadelphia chromosome-positive acute myeloid leukemia with imatinib mesylate / 대한내과학회지
Korean Journal of Medicine
;
: 132-137, 2010.
Article
Dans Anglais
| WPRIM
| ID: wpr-86562
ABSTRACT
Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) is a rare disease characterized by a poor prognosis with resistance to standard chemotherapy. We report a patient with Ph+AML with a minor BCR-ABL-positive mRNA transcript who achieved a hematologic, cytogenetic, and major molecular complete response after cytarabine-based chemotherapy followed by imatinib. After more than 6 months of continuous imatinib therapy, the patient is in continuous complete remission. Our results show that imatinib mesylate is effective in treating Ph+AML.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pipérazines
/
Pronostic
/
Pyrimidines
/
Benzamides
/
Chromosome Philadelphie
/
ARN messager
/
Leucémie aigüe myéloïde
/
Leucémies
/
Philadelphie
/
Méthanesulfonates
Type d'étude:
Étude pronostique
Limites du sujet:
Humains
Pays comme sujet:
Amérique du Nord
langue:
Anglais
Texte intégral:
Korean Journal of Medicine
Année:
2010
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS